About Autobahn Therapeutics
Autobahn Therapeutics is a company based in San Diego (United States) founded in 2019.. Autobahn Therapeutics has raised $227.53 million across 4 funding rounds from investors including Pfizer, ARE and Biogen. Autobahn Therapeutics offers products and services including ABX-002, ABX-101, and ABX-003. Autobahn Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Harmony Biosciences, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$227.53 M (USD)
in 4 rounds
-
Latest Funding Round
$100.83 M (USD), Series C
Jun 20, 2024
-
Investors
Pfizer
& 16 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Autobahn Therapeutics
Autobahn Therapeutics offers a comprehensive portfolio of products and services, including ABX-002, ABX-101, and ABX-003. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for adjunctive treatment of bipolar depression.
Next-generation S1P modulator for CNS disorders.
Regenerative medicine targeting brain disorders.
Unlock access to complete
Unlock access to complete
Funding Insights of Autobahn Therapeutics
Autobahn Therapeutics has successfully raised a total of $227.53M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $100.83 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $100.8M
-
First Round
First Round
(01 Jun 2019)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series C - Autobahn Therapeutics | Valuation | Newpath Partners | |
| Sep, 2022 | Amount | Series B - Autobahn Therapeutics | Valuation | Arch Venture Partners , Pfizer | |
| Jun, 2020 | Amount | Series B - Autobahn Therapeutics | Valuation | Arch Venture Partners , Cowen |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Autobahn Therapeutics
Autobahn Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, ARE and Biogen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services are offered by Newpath Partners.
|
Founded Year | Domain | Location | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Monograph Capital is focused on life sciences investment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Autobahn Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Autobahn Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Autobahn Therapeutics Comparisons
Competitors of Autobahn Therapeutics
Autobahn Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Harmony Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for rare neurological diseases
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Autobahn Therapeutics
Frequently Asked Questions about Autobahn Therapeutics
When was Autobahn Therapeutics founded?
Autobahn Therapeutics was founded in 2019.
Where is Autobahn Therapeutics located?
Autobahn Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Autobahn Therapeutics?
Kevin Finney is the current CEO of Autobahn Therapeutics.
Is Autobahn Therapeutics a funded company?
Autobahn Therapeutics is a funded company, having raised a total of $227.53M across 4 funding rounds to date. The company's 1st funding round was a Series B of $76M, raised on Jun 01, 2019.
What does Autobahn Therapeutics do?
Autobahn Therapeutics was founded in 2019 and is based in San Diego, United States. Regenerative medicine is utilized to develop therapeutics targeting central nervous system disorders. The pipeline features ABX-002, which addresses thyroid hormone and myelin biology for multiple sclerosis and adrenomyeloneuropathy treatments. A platform is employed to create orally administered prodrugs that modulate brain chemistry for CNS disease applications.
Who are the top competitors of Autobahn Therapeutics?
Autobahn Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Autobahn Therapeutics offer?
Autobahn Therapeutics offers ABX-002, ABX-101, and ABX-003.
Who are Autobahn Therapeutics's investors?
Autobahn Therapeutics has 17 investors. Key investors include Pfizer, ARE, Biogen, TD Securities, and Arch Venture Partners.